Journal of Glaucoma posts iStent 3‑year

Glaucoma surgery is really a pressure-management problem. The eye keeps making fluid, pressure builds, and over time that can damage the optic nerve for good. The appeal of iStent is simple — add a tiny trabecular bypass during cataract surgery and maybe lower pressure or reduce drops without jumping straight to a bigger filtering operation. What changed here is that Journal of Glaucoma pushed a 3-year dataset in Asian eyes that tries to judge success in a more realistic way than one average pressure number. (read.qxmd.com) ### What is iStent actually trying to do? iStent is a micro-bypass implant placed into the trabecular meshwork, basically trying to improve outflow through the eye’s natural drainage pathway. In practice, surgeons often place it at the same time as phacoemulsification — standard cataract surgery — because (read.qxmd.com)ster recovery than traditional glaucoma surgery. (link.springer.com) ### Why isn’t a 3-year follow-up routine? Because most MIGS papers are short. You get 6 months, maybe 12, sometimes 24. But glaucoma is a years-long disease, and early wins can fade. A device can look good right after surgery partly because cataract extraction itself lowers intraocular pressure. By 3 years, you get closer to the question surgeons actually care about — did the benefit stick once the easy early effect wore off? (link.springer.com) ### Why does the Asian-eye angle matter? Because baseline pressure and glaucoma subtype matter a lot. In Japan especially, primary open-angle glaucoma often means normal-tension glaucoma, where starting pressure may already be in the mid-teens. If a patient begins at 16 mmHg, a huge percentage drop is harder to achieve than in someone starting at 24. That makes “mean IOP fell by X%” a blunt tool. The same surgery can(link.springer.com)out escalation. (pmc.ncbi.nlm.nih.gov) ### So what is “multidimensional” success? Basically, it treats glaucoma surgery like a bundle of goals instead of one scoreboard. The study highlighted in the Journal of Glaucoma title uses success metrics that combine pressure control, medication reduction, and whether the patient avoids additional surgery over time. That is closer to real clinic logic. A surgeon is not asking only, “Did pressure fall?” The surgeon is ask(pmc.ncbi.nlm.nih.gov)xt operation?” (read.qxmd.com) ### What do longer-term Asian data already suggest? The broad pattern is encouraging but not dramatic. A 2024 registry analysis of 123 Asian eyes found lower mean IOP, fewer medications, and 40% medication-free at 12 months, though 8.2% still needed another procedure within a year. A separate 3-year Japane(read.qxmd.com)ure: useful durability, but not a miracle procedure. (link.springer.com) ### What’s the catch with reading these results? Most of these datasets are retrospective and nonrandomized. They also mix device generations, glaucoma severities, and surgeon technique. That means the findings are directionally useful, but they do not settle the head-to-head question against other MIGS options like Hydrus, or against cataract surgery alone in every subgroup. The signal is real — but the edges are fuzzy. (lifescience.net) ### Who should care about this? Cataract surgeons and glaucoma specialists, obviously, but also patients deciding whether to add MIGS during cataract surgery. The practical value of a 3-year paper is expectation-setting. If the goal is to get off every drop forever, this may disappoint. If the goal is to shave off medication burden, preserve target pressure, and delay more invasive surgery, the case looks stronger. (read.qxmd.com) ### Bottom line? This is less a breakthrough than a better measuring stick. The important part is not just that iStent plus phaco can still help at 3 years in Asian eyes. It is that the paper judges success the way glaucoma is actually managed — as pressure, drops, and durability together. (read.qxmd.com)